vs
Side-by-side financial comparison of FIRST MID BANCSHARES, INC. (FMBH) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Twist Bioscience Corp is the larger business by last-quarter revenue ($103.7M vs $88.2M, roughly 1.2× FIRST MID BANCSHARES, INC.). FIRST MID BANCSHARES, INC. runs the higher net margin — 26.8% vs -29.4%, a 56.3% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs 3.4%). FIRST MID BANCSHARES, INC. produced more free cash flow last quarter ($124.0M vs $-34.8M).
First Mid Bancshares Inc. is a U.S.-headquartered regional financial services holding company. It provides full-range retail and commercial banking products, wealth management, insurance solutions, and agricultural financing, mainly serving individual consumers, small and medium-sized enterprises, and agricultural clients across multiple Midwestern states including Illinois, Missouri, and Indiana.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
FMBH vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $88.2M | $103.7M |
| Net Profit | $23.7M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | 34.0% | -31.7% |
| Net Margin | 26.8% | -29.4% |
| Revenue YoY | 3.4% | 16.9% |
| Net Profit YoY | 23.5% | 3.4% |
| EPS (diluted) | $0.98 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $88.2M | $103.7M | ||
| Q3 25 | $89.3M | — | ||
| Q2 25 | $87.5M | — | ||
| Q1 25 | $84.3M | — | ||
| Q4 24 | $85.3M | — | ||
| Q3 24 | $80.6M | — | ||
| Q2 24 | $79.2M | — | ||
| Q1 24 | $79.9M | — |
| Q4 25 | $23.7M | $-30.5M | ||
| Q3 25 | $22.5M | — | ||
| Q2 25 | $23.4M | — | ||
| Q1 25 | $22.2M | — | ||
| Q4 24 | $19.2M | — | ||
| Q3 24 | $19.5M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $20.5M | — |
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 34.0% | -31.7% | ||
| Q3 25 | 32.2% | — | ||
| Q2 25 | 34.4% | — | ||
| Q1 25 | 33.4% | — | ||
| Q4 24 | 29.7% | — | ||
| Q3 24 | 31.5% | — | ||
| Q2 24 | 33.7% | — | ||
| Q1 24 | 33.7% | — |
| Q4 25 | 26.8% | -29.4% | ||
| Q3 25 | 25.2% | — | ||
| Q2 25 | 26.8% | — | ||
| Q1 25 | 26.3% | — | ||
| Q4 24 | 22.5% | — | ||
| Q3 24 | 24.2% | — | ||
| Q2 24 | 24.9% | — | ||
| Q1 24 | 25.6% | — |
| Q4 25 | $0.98 | $-0.50 | ||
| Q3 25 | $0.94 | — | ||
| Q2 25 | $0.98 | — | ||
| Q1 25 | $0.93 | — | ||
| Q4 24 | $0.81 | — | ||
| Q3 24 | $0.81 | — | ||
| Q2 24 | $0.82 | — | ||
| Q1 24 | $0.86 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $197.9M |
| Total DebtLower is stronger | $354.5M | — |
| Stockholders' EquityBook value | $958.7M | $456.1M |
| Total Assets | $8.0B | $638.1M |
| Debt / EquityLower = less leverage | 0.37× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $197.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $354.5M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $958.7M | $456.1M | ||
| Q3 25 | $932.2M | — | ||
| Q2 25 | $894.1M | — | ||
| Q1 25 | $870.9M | — | ||
| Q4 24 | $846.4M | — | ||
| Q3 24 | $858.5M | — | ||
| Q2 24 | $813.6M | — | ||
| Q1 24 | $798.0M | — |
| Q4 25 | $8.0B | $638.1M | ||
| Q3 25 | $7.8B | — | ||
| Q2 25 | $7.7B | — | ||
| Q1 25 | $7.6B | — | ||
| Q4 24 | $7.5B | — | ||
| Q3 24 | $7.6B | — | ||
| Q2 24 | $7.6B | — | ||
| Q1 24 | $7.7B | — |
| Q4 25 | 0.37× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $130.9M | $-24.8M |
| Free Cash FlowOCF − Capex | $124.0M | $-34.8M |
| FCF MarginFCF / Revenue | 140.6% | -33.5% |
| Capex IntensityCapex / Revenue | 7.8% | 9.6% |
| Cash ConversionOCF / Net Profit | 5.53× | — |
| TTM Free Cash FlowTrailing 4 quarters | $207.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $130.9M | $-24.8M | ||
| Q3 25 | $33.0M | — | ||
| Q2 25 | $7.7M | — | ||
| Q1 25 | $47.9M | — | ||
| Q4 24 | $124.4M | — | ||
| Q3 24 | $33.1M | — | ||
| Q2 24 | $24.0M | — | ||
| Q1 24 | $29.0M | — |
| Q4 25 | $124.0M | $-34.8M | ||
| Q3 25 | $31.9M | — | ||
| Q2 25 | $6.0M | — | ||
| Q1 25 | $46.0M | — | ||
| Q4 24 | $119.5M | — | ||
| Q3 24 | $32.0M | — | ||
| Q2 24 | $22.9M | — | ||
| Q1 24 | $27.6M | — |
| Q4 25 | 140.6% | -33.5% | ||
| Q3 25 | 35.8% | — | ||
| Q2 25 | 6.8% | — | ||
| Q1 25 | 54.5% | — | ||
| Q4 24 | 140.0% | — | ||
| Q3 24 | 39.7% | — | ||
| Q2 24 | 28.9% | — | ||
| Q1 24 | 34.5% | — |
| Q4 25 | 7.8% | 9.6% | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 2.3% | — | ||
| Q4 24 | 5.8% | — | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 1.9% | — |
| Q4 25 | 5.53× | — | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 0.33× | — | ||
| Q1 25 | 2.16× | — | ||
| Q4 24 | 6.49× | — | ||
| Q3 24 | 1.70× | — | ||
| Q2 24 | 1.21× | — | ||
| Q1 24 | 1.42× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FMBH
Segment breakdown not available.
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
